Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × lenvatinib × Gynecologic × Clear all

Phase

Status

Recruiting 8 Completed 7 Active not recruiting 6 Not yet recruiting 4 Unknown 3 Terminated 2 Withdrawn 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 9 Tumor-Agnostic 1 Thoracic 1 Sarcoma 1 Gynecologic 1 Genitourinary 1 Breast 1

Conditions

Endometrial Neoplasms 1

Interventions

Paclitaxel 19 Carboplatin 19 Radiotherapy 11 Cisplatin 11 Bevacizumab 9 olaparib 6 Taxes 6 Cyclophosphamide 6 pembrolizumab 5 niraparib 5 Magnetic Resonance Spectroscopy 5 Biopsy 5 dostarlimab 4 aldesleukin 4 Specimen Handling 4 Doxorubicin 4 talazoparib 3 fludarabine 3 Topotecan 3 Radiation 3 Metformin 3 Letrozole 3 Hyperthermic Intraperitoneal Chemotherapy 3 Gemcitabine 3 Fulvestrant 3 Colposcopy 3 veliparib 2 sitravatinib 2 palbociclib 2 liposomal doxorubicin 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03005015 2016-12-29

Lenvatinib in Second Line Endometrial Carcinoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Withdrawn

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡